Abstract 25P
Background
Circulating tumor DNA (ctDNA) refers to small fragments of DNA, shed from tumor cells into the bloodstream. Measuring it can serve as a non-invasive tool for real-time monitoring of disease dynamics. CtDNA levels have been reported to be predictive of overall survival (OS) in patients with very rare metastastic uveal melanoma (MUM), treated with tebentafusp (Carvajal et el.,2022). Here, we investigate if ctDNA is predictive of progression free survival (PFS) and OS in patients with MUM treated with any therapy.
Methods
Samples from patients treated for MUM at three academic centers were analyzed using a commercially available IVDR-certified digital PCR test. This test includes an integrated analysis software to ensure standardized data analysis across samples and enables the quantification of ctDNA for GNAQ Q209L, GNAQ Q209P and GNA11 Q209L mutations. Patients with at least 2 available samples and clinical data were included.
Results
576 samples from 72 patients with rare MUM were analyzed. 37 patients had GNA11 Q209L, 19 – GNAQ Q209P, and 16 – GNAQ Q209L mutation. 37 patients had baseline samples prior to first-line treatment, 27 of which had detectable levels of ctDNA. Out of 52 patients with baseline samples prior to any line of therapy, 40 had detectable levels. In the first line cohort, non-detectable baseline ctDNA was predictive of better PFS (p = 0.02, and a hazard ratio of 0.28 with p = 0.025) and OS (p = 0.03, and a hazard ratio of 0.14 with p = 0.058). Baseline ctDNA was also predictive for PFS and OS of non first-line therapies (p = 0.03 and p = 0.01).
Conclusions
ctDNA levels have a significant predictive value for PFS and OS in metastatic uveal melanoma, treated with first or subsequent lines of therapy. It provides a non-invasive method to predict outcome.
Legal entity responsible for the study
University Medical Center Hamburg-Eppendorf and University Hospital Zürich.
Funding
Oncobit AG.
Disclosure
J. Kött: Financial Interests, Personal, Speaker’s Bureau, outside the submitted work; BMS, Sanofi, SUN Pharma, Pierre Fabre. S. Freiberger, S. Orjuela: Financial Interests, Personal, Full or part-time Employment: Oncobit AG. R. Dummer: Financial Interests, Personal, Advisory Board, outside the submitted work; Novartis, MSD, BMS, Roche, Amgen, Takeda, Pierre Fabre, Sun Pharma, Sanofi, Catalym, Second Genome, Regeneron, Alligator, T3 Pharma, MaxiVAX SA, Pfizer, Simcere, touchIME. R. Sullivan: Financial Interests, Personal, Research Grant, outside the submitted work; Merck; Financial Interests, Personal, Advisory Board, outside the submitted work; Merck, Marengo, Novartis, Pfizer, Replimune. M.P. Levesque: Financial Interests, Personal, Research Funding, outside the submitted work; Roche, Novartis, Molecular Partners, Scailyte; Financial Interests, Personal, Research Funding: Oncobit. C. Gebhardt: Financial Interests, Personal, Advisory Board, outside the submitted work; Almirall, Amgen, Beiersdorf, BioNTech, BMS, Immunocore, Janssen, MSD, Novartis, Pierre Fabre, Regeneron, Roche, Sanofi, SUN Pharma, Sysmex; Financial Interests, Personal, Research Funding, outside the submitted work; BMS, Novartis, Regeneron, Sanofi. All other authors have declared no conflicts of interest.
Resources from the same session
7P - ACOX2 disturbs the stability of MRE11-RAD50-NBS1 complex and shapes activated immune tumor microenvironment in clear cell renal cell carcinoma
Presenter: Shiqi Ye
Session: Poster Display session
Resources:
Abstract
9P - CXCR6+PD-1- Tissue Resident memory T cells are associated with poor prognosis in patients with metastatic colorectal cancer
Presenter: Emilien Laloy
Session: Poster Display session
Resources:
Abstract
10P - Tumor-infiltrating lymphocytes and tertiary lymphoid structures in oral cavity squamous cell carcinoma in non-smokers and non-drinkers: Predict clinical outcome
Presenter: Israa Laklouk
Session: Poster Display session
Resources:
Abstract
11P - Tumor-infiltrating lymphocytes on routine H&E staining with automated quantification predict outcomes in resectable non-small cell lung cancer
Presenter: Guus Heuvel
Session: Poster Display session
Resources:
Abstract
12P - Epithelial-mesenchymal transition facilitates response to AXL/PD-1 inhibition in relapsed mesothelioma
Presenter: Essa Baitei
Session: Poster Display session
Resources:
Abstract
14P - Integrated genomic analysis of whole genomes to derive a biomarker of durable response to immunotherapy in melanoma
Presenter: Irene Lobon
Session: Poster Display session
Resources:
Abstract
15P - Verteporfin might potentiate the effects of anti-PD-1 therapy in melanoma-bearing mice model
Presenter: Szonja Kovács
Session: Poster Display session
Resources:
Abstract
16P - Immune checkpoint blockade and HLA-related epistasis in melanoma: Genetic determinants of response and toxicity
Presenter: Martin Little
Session: Poster Display session
Resources:
Abstract
17P - Identification PD-L1-associated lncRNA biomarkers for immunoregulation in ovarian cancer
Presenter: Hee Jung Kim
Session: Poster Display session
Resources:
Abstract
19P - Genetic profiling of early triple-negative breast cancer patients with an indication for neoadjuvant pembrolizumab
Presenter: Bogdan Popescu
Session: Poster Display session
Resources:
Abstract